How should I adjust the basal insulin (Basaglar) and prandial insulin (Humalog U200) for a patient whose A1c is 8.6% and whose continuous glucose monitor (Libre) shows only 14% time in range with 86% of readings high?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Aggressive Insulin Intensification Required

With an A1c of 8.6% and only 14% time in range (TIR) with 86% high readings, you need to substantially increase both basal and prandial insulin doses immediately—this patient is severely undertreated and at risk for long-term microvascular complications. 1

Immediate Action Plan

Step 1: Optimize Basal Insulin (Basaglar) First

The CGM data showing 86% high readings indicates inadequate basal coverage. Your priority is achieving fasting plasma glucose (FPG) control:

  • Increase Basaglar by 10-20% immediately (or 4 units if current dose is <40 units) 1
  • Titrate upward by 2 units every 3 days until FPG reaches 70-130 mg/dL 1
  • Monitor overnight CGM patterns—if glucose rises from bedtime to morning, basal is insufficient
  • Continue aggressive titration; don't stop at modest improvements

Critical pitfall: The 2025 ADA guidelines explicitly warn against "overbasalization"—but this patient is nowhere near that. Signs of overbasalization include elevated bedtime-to-morning differential, hypoglycemia, or high glucose variability 1. With 86% high readings, you're far from this concern.

Step 2: Intensify Prandial Insulin (Humalog U200)

Once FPG approaches target (or simultaneously if A1c >8% as in this case), aggressively address postprandial hyperglycemia:

If patient is already on prandial insulin:

  • Increase each meal dose by 10-15% (or 1-2 units per injection) 1
  • Focus first on the meal causing the largest glucose excursion per CGM data
  • Titrate every 3-5 days based on 2-hour postprandial readings

If starting prandial insulin:

  • Begin with 4 units before the largest meal OR 10% of current basal dose 1
  • Add second meal dose within 1-2 weeks if A1c remains >7.5%
  • Progress to full basal-bolus (three meal doses) if needed

Step 3: Reassess in 3-6 Months Maximum

The 2025 guidelines emphasize avoiding therapeutic inertia by reassessing every 3-6 months 1. With this degree of hyperglycemia, schedule follow-up in 6-8 weeks to review CGM data and adjust further.

Dosing Specifics

Basal insulin adjustments:

  • If A1c >8% (as here): Increase by 10-20% or 4 units, whichever is greater 1
  • Continue titrating 2 units every 3 days until FPG <130 mg/dL 1
  • For hypoglycemia: Reduce by 10-20% and identify cause 1

Prandial insulin adjustments:

  • Start: 4 units or 10% of basal dose 1
  • Titrate: Increase by 1-2 units or 10-15% every 3-5 days 1
  • If A1c <8%, consider reducing basal by 4 units when adding prandial to prevent hypoglycemia 1—but this patient's A1c is 8.6%, so maintain or increase basal

Additional Considerations

Consider GLP-1 RA addition: If not already prescribed, adding a GLP-1 receptor agonist or dual GIP/GLP-1 RA can improve glycemic control while reducing insulin requirements and weight gain 1. This is particularly relevant given the magnitude of hyperglycemia.

Glucagon prescription: Ensure patient has glucagon available as insulin doses increase 1

CGM utilization: The 14% TIR is critically low (target >70%). Use the ambulatory glucose profile to identify specific timing of hyperglycemia—overnight highs suggest basal insufficiency, postprandial spikes indicate inadequate prandial coverage 2

Why This Aggressive Approach

Research shows that patients converting to Basaglar from other basal insulins require similar or slightly higher doses (mean increase of 2 units in type 2 diabetes) 3. The current regimen is clearly insufficient given the CGM data. The 2025 ADA guidelines explicitly state that when A1c is >8%, therapeutic inertia must be avoided through regular reassessment and modification every 3-6 months 1.

Bottom line: This patient needs immediate, substantial increases in both basal and prandial insulin. Start with 10-20% basal increase, titrate aggressively every 3 days, and simultaneously optimize prandial dosing. The goal is FPG 70-130 mg/dL and TIR >70% within 3 months.

Related Questions

How do I transition a patient receiving 32 U of Levemir (insulin detemir) to Basaglar (insulin glargine)?
In a 47-year-old, 99-kg patient with type 2 diabetes on insulin glargine (Lantus) 18 U, insulin‑sensitivity factor 25 mg/dL per unit, and insulin‑to‑carbohydrate ratio 1 U per 10 g, who ate 66 g carbohydrate at 5 pm and has blood glucose readings of 231 mg/dL at 8 pm, 240 mg/dL at 9 pm, and 201 mg/dL at 1 am and will be NPO after midnight, what should the basal insulin dose, insulin‑sensitivity factor, and insulin‑to‑carbohydrate ratio be adjusted to?
With an A1c of 10.6% while taking insulin glargine (Lantus) 42 units twice daily and insulin aspart for meals, how much should the basal insulin dose be increased?
How should the insulin regimen be adjusted for a patient with a recent A1C of 10% who is currently on sliding‑scale insulin and insulin glargine (100 U/mL)?
I take 28 units of insulin glargine (basal insulin) once daily in the morning and my hemoglobin A1c is 7.1%; should I continue this dose or adjust it?
How should the insulin regimen be adjusted for a patient who is using Basaglar (insulin glargine) as basal insulin and Humalog (insulin lispro) U200 40 units three times daily before meals?
What is the appropriate workup and management for postoperative diarrhea in a patient with multiple myeloma after cholecystectomy?
How is the Wells clinical score calculated to estimate the probability of pulmonary embolism and how are the score categories interpreted?
What is the best conservative management for a plantar blister in an athlete?
In a patient with multiple myeloma, is lenalidomide administered intravenously?
In hemodynamically stable patients with acute intermediate‑risk pulmonary embolism, how many out of 100 are expected to experience clinical deterioration?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.